Immunity to Hepatitis B Vaccine (HVP01)

Identification of Age-dependent Mechanism of Vaccine-induced Immunity to a Single Dose of Hepatitis B Vaccine Using a Systems Biology Approach - a Demonstration Project

Infection and cancer is a major cause of death and morbidity, and may be preventable through vaccination. It is not fully understood at the molecular level why some people respond better than others to vaccines until now the technology to assess this has not been available. This has impaired vaccine development. The overall goal of the Human Vaccines Project is to understand the 'rules' of how vaccines work. In this demonstration project the investigators will vaccinate healthy adults with hepatitis B vaccine to start to understand better how it works, ultimately helping with rational vaccine design in the future.

Study Overview

• Status: Completed
• Conditions: Hepatitis B; Immunization; Infection
• Intervention / Treatment: Drug: Hepatitis B vaccine

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 4

Contacts and Locations

Study Locations

• Canada
  • British Columbia
    • Vancouver, British Columbia, Canada, V5Z 4H4
      • Vaccine Evaluation Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 80 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Healthy adult, corresponding to one of the study age groups.
• No history of hepatitis B disease.
• No prior receipt of any hepatitis B-containing vaccine.
• Undetectable level of anti-HBs and anti-HBc antibody and HBs antigen at study enrolment (indicating no evidence of prior hepatitis B vaccination or infection).
• Generally good health (stable chronic conditions acceptable), living independently or with minimal assistance (Clinical Frailty score 1-5) and able to attend clinic appointments.
• Willing and able to comply with the requirements of the protocol.
• Has given informed consent for participation in the study.

Exclusion Criteria:

The participant may not enter the study if ANY of the following apply:

• Individual who is on the delegation log for this study
• History of being a household contact of a known hepatitis B-infected individual.
• Planned administration of any vaccine not specified in the study protocol from 1 month pre- to the 1 month post-1st dose of vaccine.
• Planned receipt of any investigational drug for the duration of the study.
• Confirmed or suspected immunodeficiency.
• A family history of congenital or hereditary immunodeficiency.
• Receipt of more than 1 week of immunosuppressants or immune modifying drugs (e.g. oral prednisolone >0.5ml/kg/day or intravenous glucocorticoid steroid) in the 3 months prior to dose 1 of vaccine. Nasal, topical or inhaled steroids are allowed.
• Currently taking any anti-platelet or anti-coagulant medications (does not include daily low-dose aspirin).
• Bleeding disorder or thrombocytopenia, that contraindicates IM injection, blood collection and/or lymph node fine needle aspiration.
• Administration of immunoglobulins within the prior 12 months and/or any other blood products within the prior 3 months or planned during the study period.
• Current pregnancy or planning to become pregnant in the 6 months post-dose 1 vaccination.
• History of allergy to any component of the vaccine.
• Unstable medical condition, as indicated by a requirement for hospitalization or a substantial medication change to stabilize said condition within previous 3 months.
• History of any neurologic disorders or seizures, including a history of Guillain-Barre syndrome.
• Clinical Frailty score of 6-7 (moderately frail or severely frail).
• Scheduled elective surgery or other procedures requiring general anaesthesia from 1 month pre- to the 1 month post-1st dose of vaccine.
• Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.
• Temporary exclusion if acute symptomatic illness in the 7 days prior to planned first vaccine dose - vaccination will be delayed, but participant can remain in the study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: BASIC_SCIENCE
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
OTHER: Group 1; Older adults, aged 61-80 years	Drug: Hepatitis B vaccine; 1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection; Other Names: ENGERIX®-B
OTHER: Group 2; Younger adults, aged 40-60 years	Drug: Hepatitis B vaccine; 1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection; Other Names: ENGERIX®-B

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Antibody response to the first dose of hepatitis B vaccine	Anti-HBs antibody level	28 days post-vaccination following the first dose of vaccine

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to cellular immune response	Immunophenotyping by flow cytometric analysis of immune cell populations, including antigen-specific T-cell and B-cell responses, and response of immune cells to various stimuli in vitro	Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination
Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to transcriptomic response	Gene expression by RNA sequencing of whole blood and single immune cells	Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination
Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to proteomic response	Proteomic analysis of plasma and white blood cells	Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination
Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to metabalomic response	Metabolomic analysis of plasma	Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination
Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to epigenetic response	Epigenetic changes in genome	Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination
Kinetics of the immune response to the first dose of hepatitis B vaccine with respect to lymph node response	Immune responses in local lymph node, and comparison with peripheral blood responses	Pre-vaccine and 14 days following first dose only
Identify the DNA sequence of B- and T- cell receptors following vaccination	DNA sequencing of T- and B- cells	Baseline (pre-vaccine) and on days 1, 3, 7 and 14 post-vaccination

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
To correlate the 'omics immune responses measured after the first dose with antibody level after the 1st and 3rd doses	Correlation of immune endpoints (all secondary endpoints - outcomes 2 to 8) at days 1, 3, 7 and 14 post-first dose of vaccine and anti-HBs antibody level 28 days after the 1st and 3rd doses of vaccine	Days 1, 3, 7 and 14 post-first dose of vaccine and 28 days after the 1st and 3rd doses of vaccine
The influence of the gut, skin, buccal and nasal microbiota on responses to a single dose of hepatitis B vaccine - microbiome measured by 16S rDNA sequencing and vaccine response measured by anti-HBS antibody	Correlation of gut, skin, buccal and nasal microbiota (obtained pre-vaccination) with HBV vaccine response.	Day 14 pre-first dose of vaccine and day 28 post-first dose of vaccine
The influence of a single dose of hepatitis B vaccine on the gut, skin, buccal and nasal microbiota - microbiome measured by 16S rDNA sequencing and vaccine response measured by anti-HBS antibody	Analysis of changes in gut, skin, buccal and nasal microbiota obtained following vaccination	Day 14 post-first dose of vaccine
The quality of the antibody response following hepatitis B vaccination, measured by antibody subclass and avidity	Analysis of antibody subclass and avidity pre-vaccine and 1 month after the 1st dose, 5 months after the 2nd dose (6 months after 1st dose) and 1 month after the 3rd dose of vaccine	Pre-vaccine and 1 month after the 1st dose, 5 months after the 2nd dose (6 months after 1st dose) and 1 month after the 3rd dose of vaccine
The genetic changes in B- and T-cells following doses of hepatitis B vaccine, measured by T cell and B cell receptpr sequencing	DNA sequencing of B- and T- cells 28 days after the 1st dose, 7 days and 5 months after the 2nd dose (6 months after the 1st dose) and 7 days and 28 days after the 3rd dose of hepatitis B vaccine	28 days after the 1st dose, 7 days and 5 months after the 2nd dose (6 months after the 1st dose) and 7 days and 28 days after the 3rd dose of hepatitis B vaccine

Collaborators and Investigators

• Sponsor: University of British Columbia
• Collaborators: University of California, San Diego; Vanderbilt University; Institut Pasteur; J. Craig Venter Institute; The Scripps Research Institute; Human Vaccines Project
• Investigators: Principal Investigator: Manish Sadarangani, University of British Columbia; Principal Investigator: Tobi Kollmann, University of British Columbia

Publications and helpful links

Helpful Links

• Related Info

Study record dates

Study Major Dates

• Study Start (ACTUAL): March 6, 2017
• Primary Completion (ACTUAL): February 1, 2018
• Study Completion (ACTUAL): February 1, 2018

Study Registration Dates

• First Submitted: March 9, 2017
• First Submitted That Met QC Criteria: March 13, 2017
• First Posted (ACTUAL): March 17, 2017

Study Record Updates

• Last Update Posted (ACTUAL): November 25, 2020
• Last Update Submitted That Met QC Criteria: November 23, 2020
• Last Verified: November 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Digestive System Diseases; RNA Virus Infections; Virus Diseases; Infections; Blood-Borne Infections; Communicable Diseases; Liver Diseases; Hepatitis, Viral, Human; Hepadnaviridae Infections; DNA Virus Infections; Enterovirus Infections; Picornaviridae Infections; Hepatitis B; Hepatitis; Hepatitis A
• Other Study ID Numbers: H17-00175

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No